For eyes with serous RD, such as central serous chorioretinopathy and age-related macular degeneration, intravitreal injection of a TRPV4 blocker could delay photoreceptor cell death until successful retinal reattachment by laser photocoagulation, photodynamic therapy, intravitreal injection of antivascular endothelial growth factor, or other treatments can be performed. Here, TRPV4 is linked to central serous retinopathy.